Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy.
adenocarcinoma
lymph node excision
lymphocele
postoperative complications
prostatic neoplasms
Journal
The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
16
4
2022
medline:
16
7
2022
entrez:
15
4
2022
Statut:
ppublish
Résumé
The purpose of this study was to investigate the effect of a surgically constructed bilateral peritoneal flap (PIF) as an adjunct to robot-assisted radical prostatectomy (RARP) and pelvic lymph node dissection (PLND) on the incidence of lymphoceles. A total of 530 men with localized prostate cancer underwent a RARP with bilateral extended standardized PLND in a prospective randomized controlled trial. In group A, a PIF was created by suturing the margins of the bladder peritoneum to the ipsilateral endopelvic fascia at 2 points on each side. In group B, no PIF was created. The patients were followed 30 and 90 days after the surgery to assess the incidence, extent and treatment of lymphoceles. Lymphoceles occurred in 22% of group A patients and 33% of group B patients (p=0.008). Symptomatic lymphoceles were observed in 3.3% of group A patients and 8.1% of group B patients (p=0.027). Lymphoceles requiring intervention occurred significantly less frequently in group A patients (1.3%) than in group B patients (6.8%, p=0.002). The median lymphocele size was 4.3 cm in group A and 5.0 cm in group B (p=0.055). No statistically significant differences were observed in minor or major complications unrelated to lymphocele, blood loss, or surgical time between groups A and B. Bilateral PIFs in conjunction with RARP and PLND significantly reduce the total incidence of lymphoceles, the frequency of symptomatic lymphoceles and the rate of associated secondary interventions.
Identifiants
pubmed: 35422136
doi: 10.1097/JU.0000000000002693
pmc: PMC9275839
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-340Commentaires et corrections
Type : CommentIn
Références
Eur Urol Oncol. 2018 Oct;1(5):443-448
pubmed: 31158086
J Endourol. 2020 Aug;34(8):821-827
pubmed: 32303137
BJU Int. 2013 Jul;112(1):81-8
pubmed: 23351148
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
Curr Urol Rep. 2014 Oct;15(10):445
pubmed: 25129450
Dtsch Arztebl Int. 2020 Apr 3;117(14):243-250
pubmed: 32449896
World J Urol. 2008 Dec;26(6):581-6
pubmed: 18777125
Eur Urol Oncol. 2021 Apr;4(2):134-149
pubmed: 33745687
Eur Urol. 2017 Feb;71(2):155-158
pubmed: 27544575
BJU Int. 2016 Jul;118(1):127-31
pubmed: 26800257
J Laparoendosc Adv Surg Tech A. 2022 Jul;32(7):721-726
pubmed: 34677080
BJU Int. 2011 Oct;108(7):1185-90
pubmed: 21489117
Urol Int. 2022;106(1):28-34
pubmed: 33567440
Eur Urol. 2006 Nov;50(5):1006-13
pubmed: 16959399
Urology. 2015 Jun;85(6):1505-9
pubmed: 26099895
Urology. 2017 Dec;110:244-247
pubmed: 28554519
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur Urol. 2021 May;79(5):595-604
pubmed: 33293077
Eur Urol. 2020 Oct;78(4):583-591
pubmed: 32747200
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Eur Urol. 2014 Jan;65(1):7-16
pubmed: 23582879
Urol Oncol. 2013 Nov;31(8):1517-21.e1-2
pubmed: 22687569
J Urol. 2007 Jun;177(6):2106-31
pubmed: 17509297